Lupin forms Strategic Partnership with MSD

Pharma Major Lupin (Lupin) and MSD, one of the world's leading players in 23-valent Pneumococcal Polysaccharide Vaccines category has formed an India-specific strategic partnership. Within the scope of the partnership, Lupin will have a non-exclusive license to market, promote and distribute MSD's 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in India.

Pneumococcal polysaccharide vaccine (PPV) addresses the need of prevention of pneumococcal disease in India with its proven efficacy and broader coverage-PPV23 provides broader coverage and has proven efficacy for prevention of pneumococcal diseases which help addresses the need of prevention of pneumococcal disease in India, based on the clinical experience since last 3 decades, PPV23 has good safety profile.

Recent India focused study showed that more than 80% of invasive serotype groups of Streptococcus pneumoniae causing disease in the elderly in India are included in the formulation of PPV 23 which makes this vaccine relevant from India perspective  and PPV23 is recommended worldwide for prevention of pneumococcal diseases in adults by leading medical societies like Advisory committee on Immunization Practices, American Diabetes Association, American Thoracic society, Geriatric society of India etc.